Seattle Genetics to Present at Two Upcoming Investor Conferences.BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN SGEN Signal/System Generator ) announced today that it will present at two upcoming investor conferences. The presentations will provide an overview of key company programs as well as recent and planned activities. Biotechnology Industry Organization Biotechnology Industry Organization or BIO was founded 1993 in Washington, DC. James C. Greenwood is BIO's current President. External links
Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak on Wednesday, October 19, 2005, at 2:00 p.m. Pacific Time at the Palace Hotel in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden . The presentation will be webcast and available both live and for replay via the company's website at www.seattlegenetics.com, under the news and investor information section. In addition, Dr. Siegall will participate in a panel "Antibody Therapeutics on the Rise: Future Antibody Technologies," at 9:10 a.m. Pacific Time on October 19th. The presentation will be available for replay via the BIO website at www.investorforum.bio.org. C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference Eric L. Dobmeier, Senior Vice President, Corporate Development, will speak on Tuesday, October 25, 2005, at 10:00 a.m. Eastern Time at the Palace Hotel in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of . The presentation will be webcast and available both live and for replay via the company's website at www.seattlegenetics.com, under the news and investor information section. About Seattle Genetics Seattle Genetics is a biotechnology company focused on the development of monoclonal antibody-based therapies for the treatment of cancer and immunologic diseases. The company is conducting clinical and preclinical development of a diverse portfolio of product candidates in a variety of oncology and immunology settings. In addition, Seattle Genetics has developed proprietary antibody-drug conjugate conjugate /con·ju·gate/ (kon´jdbobr-gat) 1. paired, or equally coupled; working in unison. 2. a conjugate diameter of the pelvic inlet; used alone usually to denote the true conjugate diameter; see (ADC (1) See A/D converter. (2) (Apple Display Connector) A peripheral connector from Apple that combines digital video display, USB and power in one cable. ) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). . The company currently has license agreements for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen and MedImmune. More information about Seattle Genetics' pipeline and technologies can be found at www.seattlegenetics.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion